Elevated atrial natriuretic peptides and early renal failure in type 2 diabetic Goto-Kakizaki rats

Metabolism: Clinical and Experimental

Volumn 48, Issue 6, 1999, Pages 771-778

  Vesely, D L ^a,b   Gower Jr , W R ^a   Dietz, J R ^a   Overton, R M ^a   Clark, L C ^a   Antwi, E K ^a   Farese, R V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CREATININE; GLUCOSE; HORMONE PRECURSOR; NITROGEN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; KIDNEY FAILURE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL;

EID: 0033063407     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90178-6     Document Type: Article

References (49)

1. Ortola FV, Ballermann BJ, Anderson S, et al: Elevated plasma atrial natriuretic peptide levels in diabetic rats: Potential mediator of hyperfiltration. J Clin Invest 80:670-674, 1987
2. Todd ME, Hebden RA, Gowen B, et al: Atrial structure and plasma ANF levels in rats with chronic diabetes mellitus. Diabetes 39:483-489, 1990
3. Allen TJ, Cooper ME, O'Brien RC, et al: Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 39:1182-1190, 1990
4. Perico N, Benigni A. Gabanelli M, et al: Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes 41:533-538, 1992
5. Sechi LA, Valentin JP, Griffin CA, et al: Receptors for atrial natriuretic peptide are decreased in the kidneys of rats with streptozotocin-induced diabetes mellitus. J Clin Invest 95:2451-2457, 1995
6. Hirata Y, Suzuki Y, Hayakawa H, et al: Participation of endogenous atrial natriuretic peptide in the regulation of urinary protein excretion in experimental diabetic rats. Clin Sci 88:413-419, 1995
7. Vesely DL: Atrial Natriuretic Hormones. Englewood Cliffs, NJ, Prentice-Hall, 1992
8. Vesely DL: Atrial natriuretic hormones originating from the N-terminus of the atrial natriuretic factor prohormone. Clin Exp Pharmacol Physiol 22:108-114, 1995
9. Vesely DL: Vessel dilator, long acting natriuretic peptide and kaliuretic peptide: New peptide hormones originating from the atrial natriuretic factor prohormone, in Vesely DL (ed): Atrial Natriuretic Peptides. Trivandum, India, Research Signpost, 1997, pp 87-110
10. Martin DR, Pevahouse JB, Trigg DJ, et al: Three peptides from the ANF prohormone NH2-terminus are natriuretic and/or kaliuretic. Am J Physiol 258:F1401-F1408, 1990
11. Vesely DL, Douglass MA, Dietz JR, et al: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce a diuresis, natriuresis, and/or kaliuresis in humans. Circulation 90:1129-1140, 1994
12. Vesely DL, Douglass MA, Dietz JR, et al: Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 78:1128-1134, 1994
13. Vesely DL, Norris JS, Walters JM, et al: Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 148:1540-1548, 1987
14. Winters CJ, Sallman AL, Meadows J, et al: Two new hormones: Prohormone atrial natriuretic peptides 1-30 and 31-67 circulate in man. Biochem Biophys Res Commun 150:231-236, 1988
15. Winters CJ, Sallman AL, Vesely DL: Circadian rhythm of prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126 in man. Chronobiol Int 5:403-409, 1988
16. Meleagros L, Gibbs JSR, Ghatei MA, et al: Increase in plasma concentrations of cardiodilatin (amino terminal pro-atrial natriuretic peptide) in cardiac failure and during recumbency. Br Heart J 60:39-44, 1988
17. Sundsfjord JA, Thibault G, Larochelle P, et al: Identification and plasma concentration of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 66:609-610, 1988
18. Vesely DL, Gower WR Jr, Giordano AT, et al: Atrial natriuretic peptides in the heart and hemolymph of the oyster, Crassostrea virginica: A comparison with vertebrates. Comp Biochem Physiol B Biochem Mol Biol 106:535-546, 1993
19. Gower WR Jr, Chiou S, Skolnick K, et al: Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites. Peptides 15:861-867, 1994
20. Vesely DL, Norsk P, Gower WR Jr, et al: Release of kaliuretic peptide during immersion-induced central hypervolemia in healthy humans. Proc Soc Exp Biol Med 209:20-26, 1995
21. Vesely DL, Arnold WC, Winters CJ, et al: Increased circulating concentration of the N-terminus of the atrial natriuretic prohormone in persons with pheochromocytomas. J Clin Endocrinol Metab 71:1138-1146, 1990
22. Vesely DL, Cornett LE, McCleod SL, et al: Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126. Peptides 11:193-197, 1990
23. Vesely DL, Sallman AL, Bayliss JM: Specific binding sites for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes. Renal Physiol Biochem 15:23-32, 1992
24. Vesely DL, Bayliss JM, Sallman AL: Human prepro atrial natriuretic factors 26-55, 56-92, and 104-123 increase renal guanylate cyclase activity. Biochem Biophys Res Commun 143:186-193, 1987
25. Waldman SA, Rapoport RM, Murad F: Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 250:14332-14334, 1984
26. + transport in rabbit inner medullary collecting duct cells: Role of prostaglandin E2. J Clin Invest 89:1411-1417, 1992
27. +-ATPase of the atrial natriuretic peptides. Endocrinology 136:2033-2039, 1995
28. +-ATPase by atrial natriuretic factor in rat renal medullary thick ascending limb of Henle's loop. Cell Biochem Funct 8:25-29, 1990
29. +-ATPase. Renal Physiol 6:295-299, 1983
30. Vesely DL, Norsk P, Winters CJ, et al: Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 192:230-235, 1989
31. Dietz JR, Nazian SJ, Vesely DL: Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distention. Am J Physiol 260:H1774-H1778, 1991
32. Vesely DL, Rovere LE, Levey GS: Activation of guanylate cyclase by streptozotocin and 1-methyl-1-nitrosourea. Cancer Res 37:28-31, 1977
33. Goto Y, Kakizaki M, Masaki N: Spontaneous diabetes produced by selective breeding of normal Wistar rats. Proc Jpn Acad 51:80-85, 1975
34. Goto Y, Kakizaki M: The spontaneous-diabetes rat: A model of noninsulin dependent diabetes mellitus. Proc Jpn Acad 57:381-384, 1981
35. Goto Y, Suzuki KI, Sasaki M, et al: GK rat as a model of nonobese, noninsulin-dependent diabetes: Selective breeding over 35 generations, in Shafrir E, Renold AE (eds): Frontiers in Diabetes Research. Lessons From Animal Diabetes (ed 2). London, UK, Libbey, 1988, pp 301-303
36. Farese RV, Standaert ML, Yamada K, et al: Insulin-induced activation of glycerol-3-phosphate acyltransferase by a chiro-inositolcontaining insulin mediator is defective in adipocytes of insulin-resistant, type II diabetic Goto-Kakizaki rats. Proc Natl Acad Sci USA 91:11040-11044, 1994
37. Villar-Palasi C, Farese RV: Impaired skeletal muscle glycogen synthase activation by insulin in the Goto-Kakizaki (G/K.) rat. Diabetologia 37:885-888, 1994
38. Avignon A, Yamada K, Zhou X, et al: Chronic activation of protein kinase C in soleus muscles and other tissues of insulin-resistant type II diabetic Goto-Kakizaki (GK), obese/aged, and obese/Zucker rats: A mechanism of inhibiting glycogen synthesis. Diabetes 45:1396-1404, 1996
39. Ostenson CG, Khan A, Efendic S: Impaired glucose-induced insulin secretion: Studies in animal models with spontaneous NIDDM, in Ostenson CG, Efendic S, Vranic M (eds): New Concepts in the Pathogenesis of NIDDM. New York, NY, Plenum, 1993, pp 1-11
40. Winters CJ, Sallman AL, Baker BJ, et al: The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 80:438-449, 1989
41. Poulos JE, Gower WR Jr, Sullebarger T, et al: Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide gene expression. Cardiovasc Res 32:909-917, 1996
42. Daggubati S, Parks JR, Overton RM, et al: Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 36:246-255, 1997
43. Vesely DL, Dietz JR, Parks JR, et al: Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 98:323-329, 1998
44. Kreisberg JI, Patel PY: The effects of insulin, glucose and diabetes on prostaglandin production by rat kidney glomeruli and cultured glomerular mesangial cells. Prostaglandins Leukot Med 11:431-442, 1983
45. Schambeian M, Blake S, Sraer J, et al: Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus. J Clin Invest 75:404-412, 1985
46. Winters CJ, Vesely DL: Change in plasma immunoreactive N-terminus, C-terminus, and 4000 dalton mid portion of atrial natriuretic factor prohormone with hemodialysis. Nephron 58:17-22, 1991
47. Lieberman JS, Parra L, Newton L, et al: Atrial natriuretic peptide and response to changing plasma volume in diabetic nephropathy. Diabetes 40:893-901, 1991
48. Yegin E, Akcay F, Yigitoglu MR, et al: Plasma atrial natriuretic peptide levels in rabbits with alloxan monohydrate-induced diabetes mellitus. Jpn Heart J 36:789-795, 1995
49. Matsubara H, Mori Y, Yamamoto J, et al: Diabetes-induced alterations in atrial natriuretic peptide gene expression in Wistar-Kyoto and spontaneously hypertensive rats. Circ Res 67:803-813, 1990